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The relative resistance of children to sepsis
mortality: from pathways to drug candidates
Rose B Joachim1,†, Gabriel M Altschuler2,†, John N Hutchinson3 , Hector R Wong4,
Winston A Hide2,3,‡,* & Lester Kobzik1,5,‡,**
Abstract
Attempts to develop drugs that address sepsis based on leads devel-
oped in animal models have failed. We sought to identify leads
based on human data by exploiting a natural experiment: the rela-
tive resistance of children to mortality from severe infections and
sepsis. Using public datasets, we identified key differences in path-
way activity (Pathprint) in blood transcriptome profiles of septic
adults and children. To find drugs that could promote beneficial
(child) pathways or inhibit harmful (adult) ones, we built an in silico
pathway drug network (PDN) using expression correlation between
drug, disease, and pathway gene signatures across 58,475 microar-
rays. Specific pathway clusters from children or adults were
assessed for correlation with drug-based signatures. Validation by
literature curation and by direct testing in an endotoxemia model
of murine sepsis of the most correlated drug candidates demon-
strated that the Pathprint-PDN methodology is more effective at
generating positive drug leads than gene-level methods (e.g.,
CMap). Pathway-centric Pathprint-PDN is a powerful new way to
identify drug candidates for intervention against sepsis and
provides direct insight into pathways that may determine survival.
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Introduction
Sepsis is a major cause of global morbidity and mortality for which
there remains no targeted therapy (Opal, 2014; Seymour &
Rosengart, 2015; Weiss et al, 2015). Central to sepsis pathophysiol-
ogy is a dysregulated host inflammatory response (Aziz et al, 2013;
Wiersinga et al, 2014; Singer et al, 2016), suggesting that host-
directed immunomodulators could be of therapeutic benefit (Delano
& Ward, 2016). There is little agreement or certainty about which
particular cells or molecules are critical to defining sepsis outcomes
(Marshall, 2014). As a result, transcriptome analyses and systems
biology approaches have been eagerly embraced as better ways to
identify drug targets for sepsis (Maslove & Wong, 2014; Sweeney
et al, 2015; Wong et al, 2015; Davenport et al, 2016). Systematic
computational analysis represents an exciting class of approaches
for prediction and discovery of novel targets and therapeutic indica-
tions (Dubus et al, 2009; Dudley et al, 2011; Hurle et al, 2013)
reflecting their ability to provide virtual access to large numbers of
compounds and data relating to the target disease (Kim, 2015).
However, the hope that “omics-based approaches” might guide
the selection of promising therapeutics to target sepsis has not yet
been realized. This is despite the fact that tools like the Connectivity
Map (CMap) and Library of Network-Based Cellular Signatures
(LINCS; Lamb et al, 2006; Prathipati & Mizuguchi, 2015), which use
gene expression signatures to identify drug candidates, have been
available for over a decade. Obstacles to progress in developing
interventions for sepsis include discordant results across human
studies focused on gene-level changes (Sweeney & Khatri, 2016), as
well as the strongly debated limitations of animal models of sepsis
for these types of analyses (Seok et al, 2013; Osuchowski et al,
2014). Here, we address these problems by using available data on
human transcriptomes together with a powerful new approach that
combines pathway-level analysis of human transcriptome samples
with subsequent in vivo verification of findings in an animal model.
We postulate that this “human-data-first” approach can improve
results compared to prior efforts that began with findings in animal
models. Our pathway-level analysis exploits a natural phenomenon
in humans to directly compare two groups with widely disparate
rates of survival from sepsis—children and adults. Using novel path-
way-centered bioinformatic tools to optimize data analysis across
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multiple platforms, we were able to identify key differences in the
responses of both age groups to sepsis as well as identify potential
therapeutics.
The comparison of data from septic children and adults arose
from a striking finding, which at first glance seems unrelated to the
problem of sepsis. Despite similar rates of infection during the 1918
influenza pandemic, children aged 5–14 experienced a remarkably
lower rate of mortality compared to adults, dubbed the “honeymoon
period” (Ahmed et al, 2007). Puberty (~ age 14 in the early 1900s)
marked the age range in which mortality increased, suggesting that
sex hormones could influence changes in fatality rates. Importantly,
the “honeymoon period” is not limited to 1918 influenza-related
resistance to mortality. Historical mortality rates are much lower in
children after various high-fatality challenges, spanning from
bubonic plague to measles. Contemporary data for trauma, the
recent Ebola outbreaks, and other severe infections (Table 1) con-
firm the resistance. In particular, these data include lower case fatal-
ity rates for children with sepsis, both when linked to specific
pathogens (e.g., candidemia, Group A streptococcal sepsis, staphy-
lococcal sepsis), and when analyzed as a broad diagnostic category
(Table 1). We postulated that the better outcomes in children reflect
age-based differences in immune and inflammatory responses,
possibly magnified by effects of more frequent co-morbidities in
adults.
To better understand the basis for this childhood resistance, we
began by identifying public datasets of transcriptome profiling
performed on blood leukocyte samples in the high vs. low survival
groups (children and adults, respectively). The analysis used Path-
print (Altschuler et al, 2013; Davis & Ragan, 2013; https://biocond
uctor.org/packages/pathprint), a tool that is robust to batch effects
and allows for comparison of gene expression at the pathway activ-
ity level across multiple array platforms. After identifying dif-
ferences in pathway activity, we applied a novel method that is built
upon the correlation of the expression of > 16,000 disease signa-
tures from the Comparative Toxicogenomics Database (CTD), the
Pharmacogenomics Knowledgebase (PharmGKB), pathway signa-
tures from Wikipathways, KEGG, Netpath and Reactome, and drug
signatures from CTD, PharmGKB, and CMap, across > 50,000 indi-
vidual microarrays—the pathway drug network (PDN). The
network neighborhood of the sepsis pathway signatures was used to
identify the drugs that were most positively or negatively linked to
high-survival (child) or high-mortality (adult) signatures. We
assessed the validity of the top drug leads by analyzing prior data
collected in preclinical animal models of sepsis and also by direct
testing for improved survival in a mouse model of fatal endotoxemic
shock.
Results
Key pathways differentiate the adult and child responses
to sepsis
A total of 12 datasets reporting transcriptome profiling of whole
blood samples from sepsis patients were identified for analysis
from The Gene Expression Omnibus (GEO) and ArrayExpress data-
bases (Barrett et al, 2013; Kolesnikov et al, 2015). The ultimate
study population included 167 adults and 95 children, composed
of 55 and 64% males, and mean ages of 59 and 8, respectively
(Table 2). The Pathprint analysis tool was used to compare activ-
ity of pathways in adults and children with sepsis. Substantial dif-
ferences in active or depressed pathways were identified, as
illustrated in Fig 1. After applying thresholds based on the greatest
age-associated differences, the four pathway clusters (A–D),
detailed in Table 3, were used for further analysis. Tables EV1–
EV3 provide additional details of Pathprint scoring and the results
for all significantly different pathways.
PDN base network: construction and benchmarking
The PDN methodology is a novel, pathway-centric drug discovery
approach that tests whether an experimental gene signature is
positively or negatively correlated to a gene signature associated
with drug treatment. It relies on a base network constructed using
the expression correlations between each of 16,150 drug, disease,
and pathway gene signatures (collected from eight different data-
bases), averaged across 58,475 publicly available human micro-
arrays. By measuring the correlation between pathway, drug, and
disease gene signatures over more than fifty thousand experiments,
one can hypothesize whether the action that regulates, or is regu-
lated by two signatures (e.g., a drug and a survival associated
phenotype), may be linked and/or have similar actions (or oppos-
ing actions in the case of negative correlation). Since no compre-
hensive gold standard exists for evaluating the relationships
between drug and disease signatures, to test the efficacy of the
new PDN approach it was necessary to construct our own bench-
mark. Our benchmarking protocol involved the comparison of
curated, known drug–disease relationships from the National Drug
File Reference Terminology (NDFRT) and Structured Product
Labels (SPL) databases (1,055 in total), with the drug–disease rela-
tionships produced by the PDN methodology. Beyond our goal of
replicating the NDFRT and SPL drug–disease relationships using
the PDN, we also compared our methodology with an alternative
approach, Network Enrichment Analysis (NEA), a method based
on gene-level curated protein–protein interactions (PPI; Alexeyenko
et al, 2012). While both the PDN and PPI network approaches
performed better than randomly assigning drug–disease relation-
ships, the PDN decisively outperformed the PPI network at low
false discovery rates (Fig EV1). Based on this benchmarking exer-
cise, true-positive rates (TPRs) and false-positive rates (FPRs) were
measured for the PDN and used to create a series of network
cutoffs (the probability at which an edge is defined as true). From
these analyses, a PDN cutoff parameter was chosen for the final
base network that yielded as high as possible TPR (40%) while
still keeping the FPR low (6%).
PDN methodology results in high rates of positively validated drugs
Once the base network was constructed and subjected to bench-
marking analysis, the next step was to challenge the network with a
set of query pathways taken from our pre-defined Pathprint clusters
A–D. Sub-networks of the PDN were constructed that contained
these cluster pathways, together with their neighborhood of
connected nodes. After several pruning steps (described in the Mate-
rials and Methods), the resulting network focuses on the gene signa-
tures that relate most strongly to our cluster pathways. Through this
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method, four network modules incorporating each of the Pathprint
clusters A–D were created, containing 45 drug leads in total
(Table 4).
This approach and other drug discovery methodologies generate
enormous quantities of possible drug leads that necessitate efficient
validation methods. Considering the large number of previous stud-
ies that have evaluated compounds for possible benefit in sepsis
using animal models, we reasoned that one metric for evaluating
the results from the PDN would be how often the identified drug
leads corresponded to agents already shown to have positive (or
negative) effects experimentally. Hence, we conducted extensive
literature curation for each of the 45 compounds or closely related
agents (e.g., ibuprofen for NSAIDs) and scored the presence of prior
publications showing benefit or harm for survival in animal models
of sepsis.
The validation efficacy of the drug list derived from Pathprint-to-
PDN analysis was compared to three other gene-level drug discov-
ery approaches as well as to a control approach (drugs selected at
random from the entire list of CMap compounds). The first, a
gene-level approach, also used PDN, but analyzed differentially
expressed genes (DEGs) generated from a standard Limma analysis
of children vs. adult transcriptomes, rather than pathway clusters
(Appendix Fig S1). We found a substantially higher rate of positives
in the list produced by a pathway-level PDN approach: 54%,
compared to 27% for the gene-level approach, and 16% for
randomly selected drugs. We also obtained up- and down-regulated
DEGs from the BarCode method (McCall et al, 2010; Table EV4), an
approach that categorizes gene expression as on or off, and used
these genes, as well as the standard DEG list to query the LINCS
database (Wang et al, 2016), a greatly expanded version of CMap
(Lamb et al, 2006). The lists of compounds expected to have a posi-
tive effect on sepsis mortality (i.e., up- and down-regulated in adults
compared to children) were also curated to assess the frequency of
prior positive results in the literature. The percentage of positive
drug leads achieved by the Pathprint-to-PDN methodology was
significantly higher than with each of the four other methods
(P < 0.02 by Fisher’s exact test). The percent positives for each of
the five categories of drug leads are summarized in Fig 2, and
Table 1. Epidemiological examples of childhood resistance to infectious and non-infectious injury.
Disorder Child vs. adult difference Child age range Adult age range Metrica References
Historic data
1918 Pandemic flu 176.2 vs. 786.5 5–14 20–34 DP100K Linder and Grove (1947)
Tuberculosis 30.3 vs. 206.9 5–14 20–34 DP100K Linder and Grove (1947)
Measles 0.05 vs. 0.5 5–15 > 20 CFR Burnet (1952)
Yellow fever 144 vs. 759 6–15 21–60 DP100K Canela Soler et al (2009)
Typhoid fever 5 vs. 25 5–15 > 20 CFR Burnet (1952)
Plague 7 vs. 28 6–10 > 16 DR Russell (1948)
Modern data
Ebola 57 vs. 81
60 vs. 72.5
5–15
5–15
20–60
> 16
CFR Rosello et al (2015)
Team et al (2015)
H1N1 2009 0.01 vs. 0.08
1.7 vs. 5.0
5–14
0–17
25–64
18–64
DHR
DP100K
Van Kerkhove et al (2011)
Shrestha et al (2011)
Group A strep sepsis 2.6 vs. 18 < 13 19–96 CFR Megged et al (2006)
Staphylococcal sepsis 2 vs. 25 < 16 > 16 CFR Denniston and Riordan (2006)
Laupland et al (2008)
Sepsis 0.9 vs. 14.5 5–14 25–54 DP100K Melamed and Sorvillo (2009)
Sepsis (with co-morbidities) 16.0 vs. 27.6 5–14 20–59 CFR Angus et al (2001)
Sepsis (without co-morbidities) 6.3 vs. 12.8 5–14 20–59 CFR Angus et al (2001)
Severe malaria 6.1 vs. 26.7 ≤ 10 21–50 CFR Dondorp et al (2008)
Trauma (MOF) 17 vs. 35 < 16 > 16 CFR Calkins et al (2002)
Acute chest syndrome (sickle cell) 1.1 vs. 4.3 < 20 > 20 CFR Vichinsky et al (1997)
Candidemia 10.1 vs. 30.2
15.8 vs. 30.6
< 16
< 18
≥ 16
> 18
CFR
CFR
Blyth et al (2009)
Zaoutis et al (2005)
Invasive pneumococcus infection 3.8 vs. 21.5 < 13 14–106 CFR Rahav et al (1997)
Chicken pox 1.3 vs. 21.3
0.4 vs. 1.6
5–14
5–14
≥ 20
15–44
CFR
CFR
Meyer et al (2000)
Joseph and Noah (1988)
Pneumonia 2.5 vs. 9.4 5–14 20–64 CFR Tornheim et al (2007)
This table shows the difference in mortality between children and adults for a variety of infectious diseases and types of injury. The age range identified as
“child” or “adult” varied across the studies. When age was more narrowly stratified for children and adults, an average mortality rate was calculated based on the
age ranges of 5–12 and 20–60, respectively.
aCFR, Case fatality rate; DP100K, Deaths per 100,000; DHR, Deaths to hospitalization ratio.
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details of the lists and references identified are provided in
Appendix Tables S1–S5.
PDN-derived therapeutic leads improve survival in murine
endotoxemic shock
To directly investigate the utility of the PDN approach, we tested 10
of the top ranked compounds generated by the Pathprint-to-PDN
method (Table EV5) for their effects on survival in an endotoxin
shock model. Our goal was to use these drugs to directly modulate
adult pathway signatures to match pathway signatures in children
and potentially improve survival. Mice were pre-treated with the
compounds as described in the Materials and Methods, followed
by intraperitoneal administration of endotoxin. Five of the 10
compounds improved survival in this model (Fig 3). In all, eight of
the 10 compounds had not been previously reported in sepsis
survival studies; three of these eight showed benefits in our endo-
toxin shock model. The remaining two compounds were likely to be
effective based on prior publications (topotecan, a water-soluble
analog of camptothecin, and chlorpromazine, similar to piperac-
etazine) and they decreased mortality as expected.
Discussion
In this study, we sought to address the dearth of effective drug treat-
ments for sepsis by combining two novel approaches, summarized
in Fig 4. Firstly, we focused on a remarkable natural experiment—
the relative resistance to mortality in children vs. adults with sepsis.
By data-mining publicly available whole blood transcriptomes, we
were able to identify key differences in pathway regulation between
the two age groups. Continuing with a pathway-centric approach,
we used pathway-based correlation to build a novel in silico drug
discovery system to find drugs that might promote beneficial path-
ways (i.e., activated in children) or inhibit harmful ones (i.e., acti-
vated in adults). Evaluation of the resulting drug list by both
curation and direct experimentation showed substantial enrichment
for promising candidates.
The profiles of the five drugs found to be effective in vivo are
diverse. Topotecan has broad anti-inflammatory effects attributed to
inhibition of topoisomerase-dependent transcriptional activity of
pathogen-induced genes (Rialdi et al, 2016). Chlorpromazine and
amitriptyline share tricyclic structure and myriad potential mecha-
nisms of action, e.g., interactions with neural receptors, but also
inhibition of acid sphingomyelinase, which has been linked to
decreased inflammation (Sakata et al, 2007). Vinpocetine is a
synthetic derivative of the vinca alkaloid vincamine, with known
anti-inflammatory properties (Jeon et al, 2010). Khellin is a folk
medicine derived from the plant Ammi Visnaga and has a fura-
nochrome structure, but benefits and mechanism(s) of action are
poorly characterized. Although four of the five agents have anti-
inflammatory properties, at least three of the five drugs that had no
effect also have reported anti-inflammatory action [topiramate
(Dudley et al, 2011), noscapine (Zughaier et al, 2010), and etha-
crynic acid (Han et al, 2005)]. Additional investigation of these
drugs (and other leads in addition to the top 10) may help identify
meaningful commonalities more precisely.
By starting with human transcriptomic data in our comparison of
children vs. adults, we substantially increased the potential value of
subsequent analyses. Effectively, our approach uses human samples
Table 2. Demographic information on datasets used for data-mining.
Study GSE no.
Age
group
Age
mean
Age
range
Sex
Total Time when sampled
Array
GPL no. ReferencesM F
28750 Adult 60 38–82 6 4 10 ≤ 24 h 570 Sutherland et al (2011)
13015 Adult 55 40–81 11 18 29 Time of diagnosis 6947 Pankla et al (2009)
10474 Adult 58 18–83 18 16 34 ≤ 48 h 571 Howrylak et al (2009)
40586 Adult 59 37–75 8 7 15 ≤ 48 h 6244 Lill et al (2013)
57065 Adult 63 29–84 19 9 28 ~ 30 min after onset shock 570 Cazalis et al (2014)
33341 Adult 58 24–91 31 20 51 Time of diagnosis 571 Ahn et al (2013)
4607 Child 8 9–11 12 6 18 ≤ 24 h 570 Cvijanovich et al (2008)
9692 Child 7 5–9 6 2 8 ≤ 24 h 570 Cvijanovich et al (2008)
26440 Child 8 5–11 18 10 28 ≤ 24 h 570 Wynn et al (2011)
26378 Child 8 5–10 18 10 28 ≤ 24 h 570 Wynn et al (2011)
13904 Child 7 5–10 5 6 11 ≤ 24 h 570 Wong et al (2009)
40586 Child 8 7–8 2 0 2 ≤ 48 h 6244 Lill et al (2013)
Summary
Adult 59 18–91 93 74 167
Child 8 5–11 61 34 95
The GEO database was queried to identify microarray transcriptome datasets from sepsis whole blood samples of adults and children. Samples from patients
aged 18–91 comprised the adult group and patients aged 5–11 comprised the children’s group. The table above specifies each study GSE no., age category, age
mean, age range, the number of male or female patients, the timing of sample acquisition in the sepsis course, the array GPL no., and the reference used to
access the original study.
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and then verifies the methodology in an animal model. The limita-
tions of using animal models (especially mice) in preclinical sepsis
studies are well recognized. Mice typically lack many of the
common features of human sepsis patients (e.g., age, comorbidities,
drug treatments, supportive care; Osuchowski et al, 2014; Efron
et al, 2015) and exhibit highly species-specific transcriptomes after
injury or sepsis (Seok et al, 2013). In addition, no model of sepsis in
mice [e.g., endotoxemia, bacterial pneumonia, cecal ligation and
puncture (CLP)] can completely replicate the physiological
responses seen in human sepsis (Dejager et al, 2011). The strategy
used here avoids reliance on an animal model of sepsis as the initial
source of genetic information for the generation of a drug candidate
list. Moreover, even the “gold standard” sepsis model, cecal ligation
and puncture (CLP), is recognized as being technically difficult and
variable; different responses are elicited from lab-to-lab or even
from person-to-person within a given laboratory.
The (admittedly also imperfect) LPS model used in these studies,
does fulfill an important criterion: It mirrors the pre- vs. post-
pubertal human epidemiology that interests us, as detailed in our
recent publication (Joachim et al, 2017). Thus, we believe that the
endotoxemia model is a sufficient tool to begin our investigation of
the underlying mechanisms driving pre-pubertal resistance.
Figure 1. Sample heatmap generated from adult vs. child comparison using Pathprint.
Pathprint analysis was used to analyze adult and child transcriptomes at the pathway level. To minimize intra-group variation and maximize inter-group variation, two
filtering criteria were set in the generation of these data: (i) to maximize homogeneity within an age group based onminimizing the standard deviation, a cutoff of SD < 0.475
in the Pathprint score was used; (ii) to maximize differences between group comparisons using t-tests, Pathprint scores between groups were only included if P < 1010. The
heatmap above was generated using the pheatmap package.
Source data are available online for this figure.
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Ultimately, we would like to expand the pre-pubertal resistance
model to a species that is more similar to humans in sensitivity to
endotoxin and sepsis—the rabbit. We especially note that a similar
resistance to mortality from LPS in pre-pubertal vs. pubertal rabbits
has been reported (Watson & Kim, 1963) although this finding was
not the focus of the cited study.
Unfortunately, due to the absence of effective drugs for human
sepsis, it is not possible to validate our method using human
data. Therefore, we instead relied on outcomes in mice for both
the in vivo testing (Fig 3) and the curation results (Table 4),
which compiled drug treatment effects in studies mostly
performed in murine models of sepsis. While imperfect, the
“reverse-translational” methodology (Efron et al, 2015) used in this
work attempts to exploit the many remaining similarities in the
murine and human responses to injury (Takao & Miyakawa, 2015).
By limiting our study to pathways identified as important in humans,
we diminish the risks of identifying murine-specific biology. Further
assessment of the efficacy of the identified drug “hits” will need to
be conducted in larger animal models and ultimately human
patients. Despite the limitations, our approach offers a substantial
improvement in isolating drugs that merit further evaluation in
preclinical assays. The child vs. adult difference in the resistance to
mortality may also prove useful as a starting point for drug discov-
ery in other severe infections and disorders (Table 1). The change
Table 3. Pathprint clusters chosen for drug candidate analysis using PDN.
Children Pathprint
score
Adults Pathprint
score
Children-adults
difference P-value
Cluster A (up in adults, down in children)
IL-2 down reg. targets (Netpath) 0.94 0.97 1.91 1.87E-88
Shigellosis (KEGG) 0.93 0.96 1.88 2.04E-88
Endocytosis (KEGG) 0.82 0.99 1.82 1.95E-56
B cell receptor down reg. targets (Netpath) 0.95 0.84 1.79 1.69E-109
Signaling by NGF (Reactome) 0.83 0.95 1.78 9.11E-66
Pathogenic Escherichia coli infection (KEGG) 0.96 0.82 1.78 1.51E-113
Pentose Phosphate Pathway (Wikipathways) 0.79 0.99 1.78 1.80E-50
EGFR1 Signaling Pathway (Wikipathways) 0.78 0.99 1.77 6.46E-57
p38 MAPK Signaling Pathway (Wikipathways) 0.80 0.95 1.75 2.91E-62
{HCLS1,17} (Static Module) 0.96 0.63 1.59 1.28E-64
Cluster B (down in adults, up in children)
{CTNNB1,130} (Static Module) 0.93 0.95 1.87 2.71E-91
Metabolism of xenobiotics by cytochrome P450 (KEGG) 0.86 0.98 1.84 2.55E-70
Drug metabolism—cytochrome P450 (KEGG) 0.84 0.96 1.81 7.02E-66
Steroid hormone biosynthesis (KEGG) 0.97 0.81 1.78 2.79E-128
Steroid Biosynthesis (Wikipathways) 0.87 0.89 1.77 3.90E-84
Cluster C (unchanged adults, down in children)
{EP300,115} (Static Module) 0.99 0.02 0.97 4.30E-75
{HDAC1,108} (Static Module) 0.99 0.02 0.97 2.46E-91
Keap1-Nrf2 Pathway (Wikipathways) 0.89 0.07 0.82 5.94E-48
Kit receptor up reg. targets (Netpath) 0.92 0.12 0.80 1.92E-52
Sulfur relay system (KEGG) 0.85 0.18 0.67 1.00E-29
TGF beta receptor up reg. targets (Netpath) 0.94 0.09 0.85 2.87E-67
Viral myocarditis (KEGG) 0.84 0.15 0.69 2.03E-32
Cluster D (unchanged adults, up in children)
{FLI1,10} (Static Module) 0.72 0.23 0.48 7.52E-15
Melanoma (KEGG) 0.77 0.12 0.65 8.98E-26
Serotonin transporter activity (Wikipathways) 0.72 0.22 0.49 1.73E-14
Statin pathway (Wikipathways) 0.96 0.08 1.04 4.30E-64
Four different clusters of pathways, generated through Pathprint analysis, were identified based on relative activation or inhibition in adults and children. The
clusters were defined as follows: cluster A): expression up in adults, expression down in children; cluster B) expression down in adults, up in children; cluster C)
expression unregulated (not significantly changed) in adults, down in children; cluster D) expression unregulated in adults, up in children. From each cluster,
pathways showing the greatest divergence between the two age groups were selected for further analysis by PDN. This selection was based on a percentage (N)
of samples that satisfied the criteria (N = 80% for clusters A–C; N = 70% for cluster D). More detailed descriptions can be found in Appendix Table S1.
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Table 4. Curation of drug lists by literature search through PubMed.
Pathprint to
drugs Cluster
Prior
data? DEGs to drugs
Prior
data? Random
Prior
data?
Fenoprofen A +/ 0297417-0002B Urapidil
Glibenclamide A + Indomethacin +/ Trifluoperazine
Asiaticoside A + SB-202190 + Metaraminol +
Topiramate A Acetohexamide + Nomegestrol
Suramin A +/ STOCK1N-35215 Coralyne
Hyoscyamine A + Emetine Citicoline
Pancuronium A Tacrine Octopamine
N-acetyl-L-leucine A Thioridazine Sulfapyridine
Mefenamic acid A + Suloctidil Butoconazole
Apigenin A + Biotin 0175029-0000
Camptothecin B + Cyclopenthiazide Tracazolate
Lincomycin B + Mebhydrolin +/ Tomatidine
Ganciclovir B Triprolidine +/ Tetroquinone
Fursultiamine B Colchicine Repaglinide
Tocainide B + Cinchonine Tiletamine
GW-8510 B Methoxamine Amikacin +
Tanespimycin B + Tanespimycin + Butirosin
Carbenoxolone B + Fluorometholone +/ Meptazinol +
Tacrolimus B + Nicardipine + Tolnaftate
Conessine B Quinpirole Fasudil +
Khellin C Cycloheximide  Enilconazole
Eldeline C Colchicine acid Sulfanilamide
Sulfathiazole C Meteneprost  Theophylline
Geldanamycin C + Puromycin Spiramycin
Cefoxitin C Digoxin Omeprazole
Procaine C + Naftidrofuryl Rolitetracycline
Procyclidine C Terfenadine Dexpropranolol +
Monorden C + Gelsemine Piribedil
Hexetidine C Sulindac +/ Sulfathiazole
Piperacetazine C + Drofenine Iobenguane
Desipramine A & C Thioguanine Dicycloverine
Cyclosporine A & C + Methylergometrine PF-0053978-00
Nifenazone A & C +/ Methotrexate Dipivefrin
Tanespimycin A & C + Ethacrynic acid Aztreonam +
Ethacrynic acid D Dexamethasone +/ Tomatidine
Noscapine D Tolazoline Bicuculline +
Tanespimycin D + 3-aminobenzamide + Ethosuximide
Mebhydrolin D Epitiostanol Meclozine
Vincamine D Benzthiazide Alimemazine
Altretamine D 0179445-0000 Monensin
Enalapril D + Lidocaine + Prestwick-691
Coralyne D + Alexidine Oxaprozin +/
Napelline D Dihydroergocristine Amiodarone
Clindamycin D + Nifurtimox Ampicillin
A literature search using PubMed was performed to compare the number of therapeutic leads, generated by both pathway- and DEG-based drug prediction
methods, which were shown to confer a survival benefit in in vivo mouse models of sepsis. Compounds were scored as follows: positive (prior studies showing
survival benefit were identified: (+); both (prior studies showing both benefit and harm to survival were identified: (+/); negative (prior studies showing only
harm to survival were identified: (); blank (no relevant studies were identified: no entry).
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in resistance is linked to the puberty transition, suggesting a role for
sex hormones. Indeed, other experimental studies from our labora-
tory support this idea (Joachim et al, 2017; Suber & Kobzik, 2017)
and indicate this topic merits further investigation in human
studies.
In addition to the drug discovery goal of this work, the differences
in pathway activation between adults and children also provide clues
to the mechanisms driving childhood resistance to mortality. The
initial pathway clusters generated through Pathprint were selected
using relatively stringent criteria to maximize differences (see Mate-
rials and Methods). Using this approach, the pathways that were
down-regulated in children in comparison to adults (Clusters A & C,
see Table 3) involved response to infections (e.g., Shigellosis, Patho-
genic Escherichia coli infection, viral myocarditis), canonical
inflammatory and oxidative stress signaling pathways (e.g., IL-2
down-regulated targets, B cell Receptor down-regulated targets, p38
MAPK Signaling Pathway, Keap1-Nrf2 Pathway, TGF beta receptor
up-regulated targets), pathways involved in growth and cell prolifer-
ation (e.g., Signaling by NGF, EGFR1 Signaling Pathway, Kit Recep-
tor up-regulated targets), and pathways involved in chromatin
modification. These pathways suggest a chronic up-regulation of the
inflammatory response in adults in comparison with children. In
general, there were fewer pathways that met our criteria for signifi-
cant up-regulation in children in comparison to adults (Clusters B &
D), and these were found to lack direct associations with inflamma-
tory/immune responses. These pathways include lipid biosynthesis
and regulation (e.g., Steroid hormone biosynthesis, Steroid
Biosynthesis, Statin pathway, cytochrome P450 activity), as well as
proto-oncogenic genes and cancer (e.g., {CTNNB1, 130} [Static
Module], {FLI1, 10} [Static Module], Melanoma [KEGG]). Using
somewhat less stringent criteria, we identified the top 50 pathways
(out of 633, ~ top 8%) that were up-regulated in adults but down-
regulated in children or vice versa (ranked by the sum of their
respective percentile ranks; Appendix Tables S1 and S2). The
inflammatory (adult) vs. metabolic (child) difference is also evident
in this comparison. The change in resistance is linked to the pubertal
transition, suggesting a key role for sex hormones. Indeed, other
experimental studies from our laboratory support this idea (Joachim
et al, 2017; Suber & Kobzik, 2017) and indicate that this topic merits
further investigation in human studies.
We were able to carry out the comparisons reported here due to
the large number of datasets available that report whole blood tran-
scriptomes in sepsis. This reflects the systemic nature of the condi-
tion, the accepted scientific importance of leukocytes in sepsis
pathogenesis, and the relative ease of obtaining blood samples.
However, whole blood transcriptomes have limitations. The expres-
sion profiles of whole blood essentially represent a weighted sum of
the patterns of gene expression for each blood cell type and patients
with sepsis exhibit heterogeneity in the leukocyte composition of
the blood. No white blood cell count data were available in the data
annotations for these studies, making us unable to directly control
for these differences between individuals. However, the overall
leukocyte differential in septic children in the 5–11 age range is very
similar to that seen in adults (Stone et al, 1985; Park et al, 2014;
Wong et al, 2015). Finally, the analysis of whole blood does not
address potentially important contributions from endothelial,
epithelial, tissue-resident immune, and parenchymal cell types
(Cavaillon & Annane, 2006).
The novel drug development strategy applied here has more
general applicability beyond sepsis. Classical approaches to under-
standing drug–disease relationships rely on experimental assays to
relate cell states and perturbations to the etiology of different
diseases, but cannot sample all possible interactions. Fully
connected approaches such as the Molecular Signature Map (Ge,
2011) quantify interactions based on overlapping gene membership.
This method successfully integrates our knowledge of gene lists but
fails to address the issue of how drug, pathway, and disease signa-
tures influence each other. We have used microarray data from the
most highly represented platforms in GEO to determine the correla-
tion of the expression of over 16,000 drugs, diseases, and pathway
gene signatures in humans. In constructing the PDN, we used partial
correlations in order to quantify the relationship between network
nodes while still accounting for the influence of the other gene
signatures. The resulting network enables us to interpret the cell as
a whole based on the relationships and flow of information among
the myriad processes occurring within it.
Prior to the development of the PDN methodology, the steps used
in the CMap pipeline have been the main transcriptome-based drug
discovery paradigm. The standard CMap pipeline tests whether an
experimentally derived up- and down-regulated gene signature is
also up- or down-regulated in a set of drug perturbation expression
data. Broadly, this is equivalent to querying whether the transcrip-
tional impact of the experiment is similar, or opposite to the
transcriptional impact of a drug in CMap. Our alternative approach
tests whether an experimental gene signature is correlated or
Figure 2. Comparison of several methods of drug candidate
identification.
Five methods of transcriptome analysis/drug candidate identification were
compared in their ability to successfully produce drug targets in at least one prior
study showing a survival benefit from sepsis. (i) Pathprint-PDN: Comparison of
pathways by Pathprint and drug candidate analysis by pathway drug network
(PDN); (ii) DEGs-PDN: Comparison of differentially expressed genes (DEGs) by
standard methods and drug candidate analysis by PDN; (iii) Random: Drugs
chosen at random from the CMap database; (iv) DEGs-LINCS: Comparison of
DEGs generated by standard methods and drug candidate analysis using LINCS
database; and (v) BarCode-LINCS: Comparison of DEGs generated by BarCode
method and drug candidate analysis using LINCS database. The three gene-level
methods were found to be no better at generating positive drugs than picking
drugs at random. All methods produced significantly lower percent positive rates
than the Pathprint-PDNmethod (P < 0.02). Prism software (GraphPad) was used
to compare the frequency of prior studies showing benefit for drug leads Fisher’s
exact tests.
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Figure 3. Validation of select PDN drug candidates in an in vivo endotoxemia model.
Therapeutic leads generated using PDNwere directly tested for survival benefit using amurinemodel of endotoxemia. Select compounds were injected 24 h before and on the
day of LPS administration, using routes and doses specified in the methods. C57bl/6 female mice were injected with a high-lethality dose of Escherichia coli LPS (38–40 lg/g)
followed by a subcutaneous injection of sterile saline. Significant differences in concentration between drug and vehicle-treated pre- and post-pubertal mice are labeled with
****P < 0.0001, ***P < 0.001, **P < 0.01, or *P < 0.05. Percent survival was compared using a log-rank Mantel–Cox test.
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anti-correlated to the gene signature associated with drug treatment.
Importantly, the correlation is measured not just in the setting of the
transcriptome data from a single experiment, but across many
experiments (over 50,000 arrays from over 2,000 experiments). The
rationale for the PDN methodology is to quantify the relationship
between two signatures across many experiments rather than
assessing their similarity in a single test. If correlation is detected,
we can hypothesize that the action that regulates, or is regulated by,
those two signatures [i.e., from the drug and from the experimental
phenotype (e.g., better survival)] may be linked and/or have a simi-
lar action (or opposing action in the case of negative correlation).
Our approach is not meant to directly replace CMap, but to
greatly expand its power by exploiting experimental linkage. CMap
can take any signature as an input, but the pre-defined array sets
upon which is tested are fixed, and also limited in scope to experi-
mentally testable perturbations. The core focus and strength of the
PDN methodology is the ability to link any pair of gene signatures
in terms of their transcriptional regulation, irrespective of their
source. We have included a range of additional gene signatures in
the analysis so that the links are not restricted to drug interactions.
In addition, the output of the method is a network, rather than a list
of pair-wise relationships, meaning that clusters of drugs can be
detected along with any closely associated pathways. The long-term
goal is to make use of the relationships between the drug, pathway,
and diseases signatures in the network to suggest mechanisms of
action for drug leads. The eventual aim is to link pathways, drugs,
mutations, and diseases all based on the same background dataset.
Limitations of this approach include some of the well-recognized
problems in meta-analysis of microarray data in general (Tseng
et al, 2012) and in sepsis specifically (Fiusa et al, 2014; Sweeney &
Khatri, 2016). The Pathprint approach overcomes some of the prob-
lems in merging data from different platforms. However, because it
Figure 4. Summary workflow.
We began by identifying publicly available datasets from transcriptome profiling experiments that analyzed blood leukocyte samples from adult and child sepsis patients.
After data processing, we used Pathprint to translate these gene expression patterns to the pathway activity level. By comparing samples at the pathway level, the Pathprint
method is robust to batch effect and allows for comparison across multiple array platforms. After identifying age-associated differences in pathway activity, we used them to
facilitate drug discovery by constructing targeted pathway drug networks (PDNs). This novel method works by incorporating our target pathways into a base network built
upon the correlation in the expression of > 16,000 disease, pathway, and drug gene signatures across > 50,000 individual microarrays. The resultant network neighborhood
was used to identify drugs with positive or negative association with high-survival (child) or high-mortality (adult) pathways, respectively. We validated top drug leads by
curating and analyzing prior data collected in preclinical models of sepsis and also by directly testing their ability to improve survival in a mouse model of fatal endotoxemia.
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cannot integrate all platforms, some sepsis studies could not be
included. The study relied on very useful, but imperfect databases.
For example, the extensive reliance of CMap (and LINCS) on cancer
cell lines may skew results. The background data used for the calcu-
lation of the PDN correlations will be subject to a similar investiga-
tion bias in the samples uploaded to the GEO database. It is also
important to note that the quantity of available transcriptomic data
(microarrays & RNA-Seq datasets) has grown (and continues to
expand daily) since the PDN base network was first constructed. A
rich collection of other approaches to data-mining exists in the liter-
ature (Pathan et al, 2015; Henriques et al, 2017; Li et al, 2017). Inte-
gration of other analytic strategies might offer additional insights,
and this exploration merits future consideration. Similarly, an
expanded PDN based on a current version of the LINCS database
(now accessed at clue.io) might provide additional power.
Indeed, the overall success rate of drugs identified by “reversal of
signature” methods is unknown, but supported by individual
successes (Iorio et al, 2013; Musa et al, 2017). A further limitation of
existing, pair-wise approaches to determine drug–disease relation-
ships, including that approach presented here, is that no mechanistic
data can be inferred. The integration of pathway and experimental
gene signatures in the network allows for the identification of tightly
connected pathway sub-networks around each drug–disease connec-
tion. Furthermore, the network allows for both negative and positive
connections to be identified, significantly distinguishing this approach
from existing overlap-based in silico methods. These features improve
the identification of drugs with synergistic effects or sets of drugs with
independent mechanisms of action on a disease, factors that are
vitally important in overcoming polygenic drug resistance.
The ultimate aim of this work was to discover novel drug candi-
dates for the treatment of sepsis by data-mining and comparing
whole blood transcriptomes from two populations with naturally
high (adults) or low (children) susceptibility to death from sepsis.
Pathways with age-specific activation were identified through Path-
print and successfully used to interrogate the pathway drug network
(PDN), which allowed for the identification of medications that
could promote beneficial pathways during sepsis (i.e., activated in
children) or inhibit harmful ones (i.e., activated in adults). Valida-
tion by literature curation and direct experimentation in endotox-
emic mice indicated that the resulting drug list contained many
promising therapeutic candidates. These findings suggest that our
unique, pathway-centric approach to drug discovery may prove a
powerful new tool in identifying novel therapeutics for sepsis and
other complex medical conditions.
Materials and Methods
Study design
The objective of this study was to collect publicly available whole
blood transcriptomes from septic adults and children, and then
employ pathway-based bioinformatics tools to identify differentially
regulated pathways and discover novel drug candidates for the treat-
ment of sepsis. The GEO and ArrayExpress databases (Barrett et al,
2013; Kolesnikov et al, 2015) were used to identify publicly avail-
able microarray transcriptome datasets from whole blood samples
of septic patients. The criteria for inclusion of microarrays were (i)
the availability of annotation data for the age of subjects, (ii) the
use of microarray platforms supported by the Pathprint tool, and
(iii) satisfactory evaluation by quality control analysis.
Pathways with age-specific activation were identified through
Pathprint and used to interrogate the base PDN. The reliability of
the PDN in its ability to identify accurate drug-disease relationships
was benchmarked against known, curated relationships from the
NDFRT and SPL databases. Further validation of the drugs identified
through the PDN methodology was performed through literature
curation as well as direct experimentation in endotoxemic mice.
All validation experiments using mice were conducted in strict
adherence with the NIH Guide for the Care and Use of Laboratory
Animals. The number of mice was chosen based on past success in
evaluating interventions to improve survival in infectious disease
models. Endpoints in these studies were survival (for over 72 h) or
mortality. Analysis of mortality included counting deceased mice as
well as humane euthanasia of mice with severe, pre-terminal
morbidity.
Transcriptome data processing
GEO and ArrayExpress databases were queried to identify micro-
array transcriptome datasets from sepsis whole blood samples.
Samples from patients aged 5–11 comprised the children’s group
while samples from patients 18 years of age or older comprised the
adult group (details of demographics and datasets used are provided
in Table 2). The age range for the children’s group was chosen
because it is similar to the 5–14 age group that showed greater
survival in the 1918 influenza pandemic (Ahmed et al, 2007), but
adjusted to reflect the earlier onset of puberty in modern times (Ong
et al, 2006; Toppari & Juul, 2010).
The main workflow began by curating datasets and metadata of
interest. This curation process involved both automated steps (e.g.,
database searches for keywords) as well as manual work to compile
and identify whether the required metadata were available (e.g., age
of subject providing sample in a given dataset). In some cases, the
authors of the individual studies were contacted to obtain such
information. The retrieved metadata were filtered and standardized
and the relevant annotations of interest extracted (i.e., age, sepsis
status, gender, data locations). The curated metadata from each
study were then combined to create a covariate table that was used
to download each sample’s expression data using the GEOquery
package in R (Davis & Meltzer, 2007). To analyze data from multiple
array platforms, differential activation of pathways was assessed
using the R package Pathprint. To identify pathways with minimal
intra-group variation and maximal inter-group variation, two filter-
ing criteria were set: (i) to maximize homogeneity within an age
group based on minimizing the standard deviation (a cutoff of
SD < 0.475 in the Pathprint score was used); (ii) to maximize dif-
ferences between group comparisons using t-tests (Pathprint scores
between groups were only included if P < 1010). Heatmaps to visu-
alize differences in pathway activation were generated using the
pheatmap package (cran.r-project.org/web/packages/pheatmap/
index.html).
A gene-level analysis was also performed on the subset of data-
sets that used the same array (Affymetrix HG-U133 Plus 2.0, GEO
accession GPL570) as follows. First, quality control and normaliza-
tion were performed using the arrayQualityMetrics (Kauffmann
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et al, 2009) and RMA packages (Irizarry et al, 2003). DEGs were
identified using Limma (Ritchie et al, 2015). The problem of batch
effects in gene expression analysis is well known (Leek et al, 2010;
Lazar et al, 2012). Pathprint addresses this issue by aggregating
expression at the level of a pre-defined pathway. In contrast, an
earlier methodology called the Gene Expression Barcode (McCall
et al, 2011) operates at the level of the gene. To allow for compar-
ison of results, the Barcode method was applied using the fRMA
package (McCall et al, 2010). Filtering by binary entropy measures
(< 0.295 for intra-group binary entropy and > 0.3 for inter-group
binary entropy) was used to identify genes with maximal expression
differences between age groups. The top up- and down-regulated
genes in the adult vs. child comparisons were used to query the
LINCS database (Duan et al, 2014). Using the percentile rank
(“mean_rankpt_2”), the top 45 compounds anti-correlated to the
adult profile were selected and subsequently evaluated for
published evidence of efficacy in sepsis models as described below.
Selection of pathways for analysis by PDN
Four different clusters of pathways, generated through Pathprint
analysis, were identified based on similar patterns of relative expres-
sion: cluster A) expression up in adults, down in children; cluster B)
expression down in adults, up in children; cluster C) expression
unregulated (not significantly changed) in adults, down in children;
cluster D) expression unregulated in adults, up in children. Path-
ways from each cluster that showed the greatest difference between
the two comparison groups were selected for further PDN analysis.
This selection was based on the percentage (N) of samples that
satisfied the criteria (N = 80% for clusters A–C; N = 70% for cluster
D). For example, the pathways selected from cluster A were up-
regulated in at least 80% of samples in adults AND down-regulated
in at least 80% of samples in children. For cluster D, use of the 80%
criterion produced only one pathway for evaluation. Hence, the
threshold was lowered to allow inclusion of the four pathways that
were up-regulated in at least 70% of the samples from children and
unregulated in adults.
Curation of gene-sets for PDN base network creation
A set of drug, disease, and pathway gene-sets were curated from the
following resources:
1 Comparative Toxicogenomics Database (CTD) (2,452 chemi-
cal/drug and 609 disease gene-sets): The CTD (Davis et al,
2017) includes curated data describing cross-species interac-
tions between chemicals and genes/proteins as well associa-
tions between chemicals, genes, and diseases. The data were
retrieved from the CTD, MDI Biological Laboratory, Salisbury
Cove, Maine, and NC State University, Raleigh, North Carolina
(http://ctdbase.org/) [5 November 2012 retrieval].
2 The Pharmacogenomics Knowledgebase (PharmGKB) (178
chemical/drug gene-sets, 78 disease gene-sets): PharmGKB
(Whirl-Carrillo et al, 2012) is a pharmacogenomics knowledge
resource that encompasses clinical information including
dosing guidelines and drug labels, potentially clinically action-
able gene–drug associations and genotype–phenotype relation-
ships. Data (updated 11/6/12) were downloaded from the
PharmGKB website (www.pharmgkb.org).
3 Connectivity Map (CMap) (12,200 chemical/drug gene-sets):
CMap (Lamb et al, 2006) is a collection of genome-wide tran-
scriptional expression data from cultured human cells treated
with bioactive small molecules. CMap contains 6,100 expres-
sion profiles representing 1,309 compounds. The data can be
retrieved from http://www.broadinstitute.org/cmap. The rank
matrix available on the website (contains 22,283 gene probes
and 6,100 samples) was used to build unique gene signatures
for each perturbation (drug treatment). Probe sets were ranked
in descending order of the ratio of the treatment-to-control
values. The probe that was most up-regulated relative to the
control was designated as top rank (#1), while the probe that
was most down-regulated relative to the control was desig-
nated as bottom rank (#22,283). Separate up- and down-
regulated gene signatures in response to each drug were
compiled using the top and bottom 1% of ranked genes,
respectively. These gene signatures served as a proxy for the
transcriptional impact of a drug and allowed for the addition of
CMap nodes to the PDN.
4 Pathprint (633 gene-sets): Gene-sets from the pathways used
by the Pathway Fingerprint (Pathprint; Altschuler et al, 2013)
were taken from the R package Pathprint (compbio.sph.harva
rd.edu/hidelab/pathprint/Pathprint.html) implemented in
Bioconductor (bioconductor.org/packages/pathprint/). The
pathway list contains gene-sets derived from a range of path-
way databases (Reactome, KEGG, Wikipathways, Netpath; see
Pathway Fingerprint for description and references), and
modules derived from a functional gene interaction network
known as “static modules” (Wu et al, 2010).
The gene-sets derived from each of the resources described
above were combined to create a library of 16,150 unique gene
signatures.
PDN base network construction
A base network was constructed using the correlation between the
expression levels of each of the 16,150 signatures, across 58,475
publicly available human microarrays (Affymetrix HGU133 Plus2)
obtained from GEO. The array set contained 2,120 experiments, the
same set of microarrays that make up the GPL570 expression back-
ground in the Pathprint package (see Bioconductor package for full
list). For each microarray, the genes were ranked by expression
level, from #1 (low expression) to T (high expression), where T is
the total number of genes in the array. The expression score, En(G),
for a gene signature, G, of size k, represented in an array by genes
g1, g2. . .gk, is defined by the mean squared rank of the member
genes, En(G) ¼ n1 
P
R2i , where Ri is the rank of gene gi in a
pathway containing n genes. The network edges are represented by
the partial correlation between each gene signature expression
score, which is the correlation coefficient between two gene signa-
ture expression scores after accounting for the influence of the other
gene signatures. The partial correlation was calculated using the R
package GeneNet, which makes use of shrinkage estimators of
partial correlation for fast and statistically efficient processing of the
data (cran.r-project.org/web/packages/GeneNet/index.html).
The significance of each of the connecting edges was assessed by
fitting a mixture model to the partial correlations, where the null
model is estimated from the data. The calculation used the R
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package, fdrtool (http://cran.r-project.org/web/packages/fdrtool/
index.html) to generate two-sided P-values for the test of non-zero
correlation for each edge, corresponding posterior probabilities for
edges, and q-values (Schafer & Strimmer, 2005). The PDN method
creates a network that is dynamic and can be extended to cover any
number of additional signatures. The network was benchmarked
using curated case–control interactions.
Network characterization
PDN network topology
The PDN degree distribution and degree cumulative probability are
shown in Fig EV2. At first glance, the degree distribution of the
PDN plotted on a log-log scale may be considered roughly linear—
indicative of a scale-free network following a power law distribution
with gamma of approximately 0.61. However, the cumulative proba-
bility plot, which would also be linear on a log-log scale under
scale-free conditions, clearly demonstrates significant divergence
from a power law distribution. An exponential distribution or power
law with exponential cutoff provides more reasonable but not exact
fits. Scale-free networks were thought to be a common characteristic
of biological networks (Albert, 2005), generally rationalized by the
hypothesis that such networks are robust to random breaks and
facilitate rapid inter-node communication by short average path
lengths and high clustering coefficients. However, as higher resolu-
tion experimental data have become available, the general scale-free
nature of biological networks has been increasingly questioned
(Lima-Mendez & van Helden, 2009). The degree distribution of the
PDN is evidence of a denser structure than would be expected from
a power-law distributed network and provides an additional exam-
ple of departure from scale-free topology. It should be noted that the
presence of the drug perturbation and disease-state signatures in the
PDN would also be expected to disrupt the structural characteristics
of a network based on canonical pathways alone.
Biological interpretation of PDN pathway relationships
We wished to establish whether pathways are correlated within the
PDN in biologically meaningful ways. We created a sub-network
consisting of all pathways from the network. Markov Clustering
(van Dongen, 2000) of pathway–pathway correlation using the
Graphia Pro environment (Kajeka.com) generated 38 biologically
consistent clusters containing between 6 and 34 pathways as nodes
(Table EV6). Pathway nodes vary in degree from 244 (Path-
way.{PRKACA,33} (StaticModule)) to 4 [Pathway.TNF-alpha/NF-kB
Signaling Pathway (Wikipathways)]. Interpretation of cluster
membership is complicated by the fact that only a partial under-
standing of known functional relationships between pathways
exists. We have begun to address this challenge in a separate study
of global pathway relationships (Pita-Juarez et al, 2018).
Clusters show pathways related by function. As cluster size
decreases, functions become more specific. One example of this can
be seen in our largest cluster, Cluster 1, which contains pathways
sharing functionality across cellular responses to stress, infections
and cancers, B and T Cell receptor signaling pathways, as well as
Tuberculosis, Leishmaniasis, and Toxoplasmosis pathways. Other
clusters are enriched for pathways in lipid metabolism (Cluster 3);
cell cycle and DNA replication (Cluster 6); immune signaling (Clus-
ter 8); DNA repair and replication and RAS family genes (Cluster
10); extracellular matrix function (Cluster 12); and electron trans-
port, respiratory chain function, oxidative phosphorylation, and
Parkinson’s disease (Cluster 14). Functional relationships between
pathways structured in this clustering approach may be insightful in
terms of providing data driven context to known relationships. For
instance, shared functionality in immune-mediated mechanisms of
stress surveillance in cancer is an existing observation (Seelige et al,
2018).
Benchmarking the PDN
In an effort to benchmark the PDN, we compiled two sets of curated
drug–disease relationships: 149 documented relationships from the
NDFRT database (46 diseases and 92 drugs) and 906 documented
relationships from the SPL database (58 diseases and 122 drugs).
The drug and disease terms from both of these databases have been
previously mapped to the PharmGKB identifiers (Zhu et al, 2013)
used in construction of the PDN. This allowed for direct comparison
of the two methods. CMap datasets have not been mapped to the
terms in the NDFRT and SPL databases and were thus not used for
benchmarking. True- and false-positive rates (TPRs, FPRs) were
measured for the PDN and used to create a series of network cutoffs,
and an ROC curve was plotted (Fig EV1). Beyond the goal of repli-
cating these drug–disease relationships using the PDN, we also
compared our methodology with an alternative approach, NEA.
Determining CMap drugs associated with query cluster pathways
Once the base network was constructed, we interrogated it with a
set of query pathways from pre-defined Pathprint clusters A–D. A
sub-network was constructed for each cluster (e.g., Cluster A) that
contained the nodes representing each of the member pathways of
that cluster, together with all base network nodes with connecting
edges to the cluster members. To assure that the new network was
specific to correlations associated with a given cluster of pathways,
we further pruned the sub-networks by removing base network
nodes if they did not connect to at least three or more of the path-
ways in the cluster. Next, we ranked the significance of the remain-
ing base nodes using the P-values of the edges connecting them to
each of the cluster nodes, aggregated by Fisher’s method. For all
non-CMap nodes, P-values were simply aggregated across the entire
pathway cluster into a single P-value. For CMap nodes, P-values
were first aggregated across the separate CMap up- and down-
regulated gene signatures for each drug and secondly across the
entire pathway cluster. An overall positive correlation between a
cluster pathway and a pair of CMap nodes was determined by
combining the P-values calculated for positive correlation with the
up-regulated CMap drug signature and negative correlation with the
corresponding down-regulated CMap drug signature. Overall, nega-
tive correlation between a cluster pathway and a pair of CMap
nodes was established in a similar way. The P-values for positive
and negative correlation were then ranked and combined into a
simple combined association score: Score = rank(negativeRank –
positiveRank)/(nDrugs/2) – 1, where negativeRank is the rank of
the negative P-value, positiveRank is the rank of the positive
P-value, and nDrugs is the number of drugs tested. Any CMap drug
with a P-value of > 0.1 for both positive and negative association
was given a score of 0. Thus, a negative score means that the drug
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opposes the activity of the cluster pathways, a positive score means
that drug enhances the activity of the cluster pathways. A score of 0
means no significant interaction. The 10 highest negatively scoring
drugs each for clusters A and C, the 10 highest positively scoring
drugs each for clusters B and D, as well as the top 5 within the over-
lap of clusters A and C (a total of 45 drugs) were prioritized for vali-
dation as described in the following section. While the PharmGKB
database also contained drug signatures, they were non-directional
(up and down-regulated genes are not distinguished). Because it
would have been impossible to distinguish a correlated vs. anti-
correlated signature using the PharmGKB signature, we chose to
perform all final analyses using the CMap signatures.
Determining CMap drugs associated with an individual
gene signature
To compare PDN functionality based on a network analysis of a
target cluster of pathways with standard single gene list-based analy-
sis, we queried the PDN directly with a differential signature derived
from adult and child transcriptomes (see above). The top 500 up-
and down- regulated probes from a comparison of children vs. adults
using datasets limited to a single array platform (GPL570) were
matched to 427 and 405 up- and down-regulated genes in CMap.
These gene signatures were incorporated into the PDN and ranked
for positive or negative association with CMap drug signatures by a
similar approach as the Pathprint cluster pathways described above.
The differentially expressed genes were split into up-regulated and
down-regulated gene-sets. These gene-sets were then introduced into
the PDN as two new nodes and evaluated separately. The P-values of
the edges connecting each of the new nodes to the separate CMap
up- and down-regulated gene signatures were aggregated for each
drug. This calculation helped to quantify whether the up- and down-
regulated components of the adult vs. child differentially expressed
signatures were positively or negatively associated with each CMap
drug. Then, an overall positive or negative correlation between a dif-
ferential gene signature and a CMap drug was determined by
combining the P-values calculated for the up-regulated and down-
regulated parts of the signature. The top 45 negatively associated
drugs were selected for further validation.
Validation of drug leads
To validate the top 45 therapeutic leads generated by each drug
discovery methodology, a literature search using PubMed was
performed. We used terms (i.e., keywords: survival, mortality,
sepsis, endotoxin) to identify studies that tested a particular drug, or
a closely related compound, for in vivo benefit in animal models of
sepsis. Compounds were scored as follows: positive (prior studies
showing survival benefit were identified); both (prior studies show-
ing both benefit and harm to survival were identified); negative
(prior studies showing only harm to survival); no score was assigned
when no relevant studies were identified. The efficacy of the Path-
print-to-PDN methodology was compared to several other transcrip-
tome-to-drug discovery approaches (described in results and Fig 2)
as well as to drugs randomly chosen from the CMap database.
Ten drugs were selected from the pool of drugs identified using
the Pathprint-to-PDN methodology. These were chosen to sample
from all clusters and to include agents both with and without prior
evidence of potential benefit. Substitutions with highly similar
compounds were made for some of the predicted drugs. For three of
the four substitutions made (topotecan, chlorpromazine, amitripty-
line), the rationale was driven by the existence of publications
showing survival benefit in animal models using the substituted
drug ((Brand et al, 2008; Rialdi et al, 2016; Villa et al, 1995),
respectively). These data did not exist for the original predicted
drugs. For the final pair, vincamine/vinpocetine, there are no
published data demonstrating a survival benefit, but there are data
showing that vinpocetine has some anti-inflammatory activity (Jeon
et al, 2010). No similar data were found for vincamine, thus moti-
vating our choice of vinpocetine.
The compounds were directly tested for effects on survival using
a murine model of endotoxemia. These experiments were conducted
in strict adherence to the NIH Guide for the Care and Use of Labora-
tory Animals, and under a protocol approved by the Harvard Medi-
cal Area Institutional Animal Care and Use Committee (IACUC).
C57bl/6 female mice (5 weeks old, Charles River, Wilmington, DE)
were injected with a high-lethality dose (e.g., 38–40 lg/g) of E. coli
LPS (L3755; Lot: 123M4096V; Sigma-Aldrich, St. Louis, MO, USA)
between hours 5 and 7 of the light period in the animal facility (12–
2 PM). In order to mitigate fluid loss and dehydration, each mouse
was also given a subcutaneous injection of sterile saline (equal to
2.5% of body weight). To test the effects of drug leads, compounds
were injected 24 h before and on the day of LPS administration,
using routes and doses specified in Table EV7. Analysis of mortality
included counting deceased mice as well as humane euthanasia of
mice with severe, pre-terminal morbidity (scored by evaluation of
appearance, movement, and response to touch).
Statistical analysis
The statistical methods used in transcriptome comparisons as well
as the creation and application of the PDN methodology are detailed
in the sections above. Fisher’s exact test was used to compare the
frequency of prior studies showing benefit for drug leads across the
multiple transcriptome-to-drug methodologies. A log-rank (Mantel–
Cox) test was used to analyze murine endotoxemia survival data.
Both of these statistical analyses were performed using Prism soft-
ware (GraphPad, San Diego, CA).
Expanded View for this article is available online.
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